Canadian scientists have developed a rapid blood test and a portable device called PowerBlade for the early detection of sepsis. Published in *Nature Communications* on May 27, 2025, this innovative technology boasts over 90% accuracy in identifying individuals at high risk of developing sepsis, a condition that accounts for approximately 20% of global deaths.
The PowerBlade device analyzes gene expression from a single drop of blood using artificial intelligence to detect a six-gene signature indicative of sepsis. Results are available in under three hours, enabling quicker intervention and improved patient outcomes. The device was tested with 30 patients, showing 92% accuracy in identifying high-risk patients and 89% accuracy in ruling out those not at risk.
This advancement allows for faster treatment in emergency rooms and remote healthcare units, potentially preventing irreversible organ damage. Developed through a collaboration between the University of British Columbia, St. Michael's Hospital, Unity Health Toronto, and the National Research Council of Canada, PowerBlade represents a significant step forward in combating sepsis and improving patient care by enabling early and accurate diagnosis.